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5-Iodo-20-deoxyuridine (IUdR) is an effective radiosensitiser but its clinical development has been limited by toxicity. Prolonged
intravenous infusions of IUdR are necessary for optimal tumour uptake but cause dose-limiting myelosuppression. The lack of
selective tumour uptake can lead to radiosensitisation of adjacent normal tissues and enhanced local radiation toxicity. Liposomal
IUdR delivery offers selective targeting of tumour tissues and avoidance of local and systemic toxicity. In these studies, we report the
development of a pegylated liposome containing a lipophilic IUdR derivative (30,5 0-O-dipalmitoyl-5-iodo-20-deoxyuridine) for use in a
head and neck cancer xenograft model. Initial studies confirmed the ability of IUdR to sensitise two head and neck cancer cell lines to
single fractions of radiotherapy (SFRT) and this effect was seen to correlate with the thymidine replacement index in KB cells. In vivo
delivery of single doses of either unencapsulated IUdR or pegylated liposomal IUdR (PLIUdR) to nude mice bearing KB xenograft
tumours did not enhance the effect of SFRT delivered 16h later. When PLIUdR was delivered by a protracted administration
schedule to a dose of 48mgkg
 1 over 7 days, it enhanced the effect of both 4.5Gy SFRT and fractionated radiotherapy. PLIUdR was
at least as effective as unencapsulated IUdR delivered by multiple intravenous injections or continuous subcutaneous infusion.
Immunohistochemistry with a specific anti-IUdR monoclonal antibody confirmed greater levels of tumour staining in tumours from
animals treated with PLIUdR compared with those treated with unencapsulated IUdR.
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Halogenated pyrimidines (HP) (5-bromo-20-deoxyuridine (BUdR)
and 5-iodo-20-deoxyuridine (IUdR)) are effective radiosensitisers
in cells that take them up (Fowler and Kinsella, 1996). They act by
being incorporated into DNA in competition with thymidine
during S phase of the cell cycle and mediate radiosensitisation by
increasing the susceptibility of IUdR- or BUdR-substituted DNA to
radiation-generated reactive free radicals, which may also damage
unsubstituted complementary-strand DNA (Fornace et al, 1990).
In addition, there is evidence that HP can inhibit the repair of
radiation-induced DNA damage (Iliakis et al, 1989). Exposure to
clinically achievable steady-state concentrations of either IUdR or
BUdR significantly increases formation of single- and double-
stranded DNA breaks in vitro (Kinsella et al, 1987). HP-mediated
radiosensitisation is directly related to the extent of thymidine
replacement in DNA (thymidine replacement index, TRI)
(Lawrence et al, 1990; Miller et al, 1992), which, in turn, is related
to the duration of drug exposure in vitro (Lawrence et al, 1990).
Phase I clinical studies using protracted intravenous infusions of
IUdR in patients with hepatic metastases, high-grade glioma,
sarcomas and head and neck cancers resulted in TRI of 4–26% in
tumour tissue, which were significantly greater than the levels in
adjacent normal tissues (Speth et al, 1988; Cook et al, 1992).
Haematological and mucosal toxicities (including exacerbation of
the local radiation response) were dose-limiting and directly
related to the duration of drug infusion (Urtasun et al, 1993;
Epstein et al, 1994; Sullivan et al, 1994). These findings may, in
part, explain the failure of intravenous infusional IUdR to yield a
survival advantage when used as a radiosensitiser in the treatment
of gliomas, head and neck cancers and sarcomas (Goffman et al,
1992; Urtasun et al, 1993; Epstein et al, 1994; Sullivan et al, 1994;
Robertson et al, 1995; Urtasun et al, 1996). In vitro data have
suggested that repeated short duration drug exposures may
provide a means of achieving effective DNA incorporation and
reducing dose-limiting myelotoxicity (Lawrence et al, 1990), but
relatively few cells will be targeted with this approach since only
cells in S phase at the time of drug administration will incorporate
the agent. Fowler and Kinsella (1996) have calculated that infusion
durations of 5–10 times greater than the population doubling time
of clonogenic cells will be required for clinically significant
radiosensitisation. Therefore, although HP appear to be a
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spromising group of agents, their efficacy is limited by the amount
of drug incorporated into the tumour with relatively short
durations of drug infusion and the occurrence of dose-limiting
systemic toxicity when more prolonged infusions are administered.
One potential means of overcoming both of these obstacles is
the development of liposome-targeted HP. The inclusion of
methoxypolyethylene glycol-derivatised (pegylated) lipids in the
bilayer membrane of liposomes effectively increases the longevity
of liposomes in the circulation (Papahadjopoulos et al, 1991) and
increases their accumulation in tumours (Huang et al, 1992).
Preclinical studies have shown that cytotoxic drugs entrapped in
pegylated liposomes are active against a range of tumours
(Harrington et al, 2000a). Clinical studies of pegylated liposomal
doxorubicin have confirmed its activity against AIDS-related
Kaposi’s sarcoma (Northfelt et al, 1998; Stewart et al, 1998) and
breast and ovarian cancers (Muggia et al, 1997; Ranson et al, 1997)
with considerable attenuation of the adverse effects of the
unencapsulated drug. Furthermore, preclinical and Phase I/II
trials of pegylated liposomal doxorubicin and radiotherapy (RT)
have supported the feasibility of this approach in head and neck
and lung cancers (Koukourakis et al, 1999; Harrington et al, 2000b, c;
Harrington et al, 2001a). In the present study, we carried out
experiments to examine the potential value of a novel prodrug
formulation of IUdR (30,5 0-O-dipalmitoyl 5-iodo-20-deoxyuridine,
dpIUdR) encapsulated in pegylated liposomes (PLIUdR) to act as a
radiation sensitiser in a human head and neck squamous cell
cancer (HNSCC) model.
MATERIALS AND METHODS
In vitro radiosensitivity assay
Human HNSCC KB and HN5 cells were grown as monolayers in
75cm
2 tissue culture flasks (Falcon, NJ, USA) in Dulbecco’s
modified Eagle’s medium supplemented with 10% fetal calf serum
(FCS) (Gibco, Paisley, UK), nonessential amino acids, and
antibiotics at 371C in a humidified incubator with 5% CO2.C u l t u r e
medium was supplied by the Media Production Unit at the Imperial
Cancer Research Fund, Clare Hall, Herts, UK. Under these
conditions, the doubling time of KB cells is approximately 17h
(data not shown). The cells were plated at low density
(5 10
4cellsflask
 1) to ensure that they were growing exponentially
during the 48h period in which they were exposed to 0, 10
 6,1 0
 5
or 10
 4 M unencapsulated IUdR (Nova Laboratories, Leicester, UK).
For the assessment of radiation survival after exposure to IUdR, the
cells were trypsinised and plated in appropriate dilutions in growth
medium in six-well plates. At 4h after plating, the cells were
irradiated (0, 4, 7Gy) with a 111TBq
137Cs source (CIS Bio
International, Gif-sur-Yvette, France) yielding a dose rate of about
2Gymin
 1. Following irradiation, the cells were incubated for 6
days, changing the culture medium on alternate days after day 3.
After this time, surviving cells were trypsinised and plated onto 96-
well microtitre plates containing 100ml of medium per well. After
incubation overnight, growth medium was removed and the wells
were washed twice with phosphate-buffered saline (PBS) and 60ml
of 3.75mM p-nitrophenyl-N-acetyl-b-D-glucosaminide (NAG) in
0.05M citrate buffer (0.1M citric acid, 0.1 M trisodium citrate,
0.25% Triton X-100, pH 5.0) was added to each well (Yagi et al,
1989). Cells were incubated at 371C and 5% CO2 for 1h, removed
from the incubator and the colorimetric reaction was stopped by the
addition of 90ml of glycine buffer (50mM glycine, 5mM EDTA, pH
10.4). The optical density was read on a Titertek Multiskan
s MCC/
340 spectrophotometer with a 405nm filter.
Thymidine replacement index
KB cells were grown as monolayers in 75cm
2 tissue culture flasks
as detailed above. The cells were plated at low density
(5 10
4cellsflask
 1) to ensure that they were growing exponen-
tially during the 48h period in which they were exposed to 0, 10
 6,
10
 5 or 10
 4 M unencapsulated IUdR. After this time, the cells were
trypsinised, centrifuged and the pellet was washed thrice with PBS
and the DNA was extracted using a QIAamp Tissue Kit (Qiagen
Ltd, Sussex, UK) according to the manufacturer’s instructions.
Digestion of DNA into deoxynucleotides was performed as follows:
100ml of the DNA preparation (containing 5–10mg DNA) was
incubated for 1h at 371C with 0.4–0.5ml DNase I (Boehringer
Mannheim, Germany) and 5ml 100mM MgCl2; 0.4ml of crotalus
venom phosphodiesterase I (Boehringer Mannheim) was added
and incubated for 1h at 371C; 0.2ml alkaline phosphatase
(Boehringer Mannheim) was added and incubated for 1h at
371C. The resulting nucleotide solution was adjusted to pH 5.5
before loading onto the HPLC column. Standard nucleotides (20-
deoxycytidine [C], 20-deoxyguanosine [G], 20-deoxyadenosine [A]
and thymidine [T]) were obtained from Sigma Chemical Co. (St
Louis, MO, USA). All HPLC experiments were performed using a
C18 Phenomenex Columbus column (2 250mm, 5mm particle
size) with UV detection at 254 and 288nm. The mobile phase
contained 10mM ammonium acetate, pH 6.0, with 8.75%
acetonitrile, pumped at a flow rate of 1mlmin
 1 at room
temperature. The deoxynucleotides and IUdR were detected at
254 and 288nm. To calibrate the peaks on the HPLC, standard
stock solutions of IUdR and deoxynucleotides were diluted to yield
several solutions with concentrations of 2 10
 4 to 2 10
 6 M and
a linear relationship was observed between the peak heights and
amounts loaded (data not shown).
Tumour xenograft model
All animal experiments were carried out with ethical committee
approval and met the standards laid out in the UKCCCR guidelines
(Workman et al, 1998). Female nude mice of mixed genetic
background bred under specific pathogen-free conditions at the
Imperial Cancer Research Fund Animal Breeding Unit (South
Mimms, Herts, UK) were used. Animals were housed in sterile
filter-top cages on sterile bedding and maintained on an irradiated
diet and autoclaved acidified water (pH 2.8) ad libitum. KB tumour
cells were grown to confluence in vitro in 175cm
2 tissue culture
flasks as detailed above. Cells were harvested and a single cell
suspension was prepared. Tumour xenografts were set up by
subcutaneous injection of 5 10
6 tumour cells in 100ml of culture
medium into the right flank of the mice. The animals were used for
experiments approximately 15 days later, at which time the
tumours were 6–8mm in diameter. Starting 7 days after
inoculation the tumours were measured on alternate days on at
least three occasions before the commencement of the study. Three
orthogonal tumour diameters were recorded using Vernier calipers
and the tumour diameter was calculated from the formula:
V ¼ p
6 d1d2d3. Therapeutic irradiation (see below) was adminis-
tered on day 15 after inoculation and the measured tumour volume
on this day was designated as the initial volume or V0.
Subsequently, the tumour volume was assessed two or three times
per week and the absolute and relative (as compared to V0) tumour
volume was calculated. Mice were killed after the tumour had
increased in size to more than three times its original volume
(3V0). The time taken to reach 3V0 was recorded and used as a
surrogate measure of animal survival and was designed to spare
the animals from the physical distress of unnecessarily large
tumour burdens and to comply with the UKCCCR guidelines
(Workman et al, 1998).
5-Iodo-20-deoxyuridine for in vivo use
Unencapsulated 5-iodo-20-deoxyuridine (Sigma-Aldrich Co. Ltd.,
Poole, UK) was dissolved in a 20% solution of dimethyl sulphoxide
in distilled water. Because of its water solubility and low molecular
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sweight, IUdR cannot be retained efficiently in liposomes.
Therefore, IUdR was derivatised by attaching two long-chain fatty
acids (palmitic acid) to the 30 and 50 positions of the IUdR sugar
moiety to form 30,5 0-O-dipalmitoyl-5-iodo-20-deoxyuridine
(dpIUdR) to convert the agent into a hydrophobic, lipid soluble
prodrug which was stably incorporated into the bilayer of
pegylated liposomes with the following lipid composition (values
expressed as a % molar ratio): HSPC (94.6%) and MPEG-DSPE
(5.4%). The agent was supplied as an isotonic, preservative-
free solution in 20ml vials at a dpIUdR concentration of
between 2.8 and 3.5mgml
 1 (equivalent to IUdR concentrations of
1.2–1.5mgml
 1).
Administration of test agents
Unencapsulated IUdR was administered either as intravenous
bolus injections or as a continuous subcutaneous infusion. The
intravenous bolus injections were administered according to the
following schedules: (1) single injections of 24mgkg
 1 given 16h
before tumour irradiation; (2) as a series of four injections of
12mgkg
 1 on alternate days to a total dose of 48mgkg
 1 over a 7-
day period before irradiation. The continuous infusions of
unencapsulated IUdR were administered using subcutaneously
implanted Alzet
s Model 2002mini-osmotic pumps (Charles River
UK, Ltd, Kent, UK) over a 7-day period before irradiation. A dose
of 48mgkg
 1 was delivered over the 7-day period
(6.9mgkgday
 1) by pumps with a mean fill volume of 22679ml
and a mean pumping rate of 0.4670.03mlh. PLIUdR was
administered as intravenous bolus injections according to the
following protocols: (1) single injections of 24mgkg
 1 given 16h
before tumour irradiation; (2) as a series of four injections of
12mgkg
 1 to a total dose of 48mgkg
 1 over a 7-day period before
irradiation. No attempt was made to deliver subcutaneous
infusions of PLIUdR.
Tumour irradiation
Tumour irradiation was performed using the
137Cs source with
mice carefully positioned within a specially constructed jig as
described previously (Harrington et al, 2000c). The system was
calibrated as previously described (Harrington et al, 2000c) with
lithium fluoride thermoluminescent dosimeters (TLD) (Nuclear
Enterprises, Reading, UK) that were read in a Toledo 654 TLD
reader (DA Pitman, Weybridge, UK) (data not shown). Before
therapeutic irradiation, the animals were anaesthetised with an
intraperitoneal injection of 100ml of a 1:1:4 mixture of Hypnorm
(fentanyl citrate 0.315mgml
 1, fluanisone 10mgml
 1) (Janssen-
Cilag Ltd, High Wycombe, UK), Hypnovel
s (midazolam
5mgml
 1) (Roche Products Ltd, Welwyn Garden City, UK) and
water for injection BP (Fresenius Health Care Group, Basingstoke,
UK). Anaesthetised animals were positioned such that the
subcutaneous xenograft tumours were exposed to the radiation
beam with the rest of the animals’ bodies shielded by 4cm thick
lead. Great care was taken to avoid direct pressure on the tumour
mass in order to minimise the risk of creating areas of pressure-
induced hypoxia during irradiation. Animals were managed at all
times in accordance with UKCCCR standards (Workman et al,
1998).
Radiotherapy alone
The effect of single fractions of RT (SFRT) was initially assessed by
irradiating groups of mice bearing KB xenograft tumours with
radiation doses of 4.5Gy (n¼17) and 9Gy (n¼12) over a period
of 385 and 770s, respectively. The RT was delivered at a dose rate
of 0.7Gymin
 1 as determined by the dosimetric calibration
outlined above. Similarly, the effect of daily fractionated RT
(FRT) to a dose of either 9Gy in three fractions over 3 days
(n¼11) or 15Gy in five fractions over 5 days (n¼10) was
determined in KB tumour-bearing mice. Again, all irradiations
were carried out at a dose rate of 0.7Gymin
 1 over a period of
257s.
Radiotherapy and IUdR
The combination of RT and IUdR was tested according to a
number of sequential protocols with the aim of modelling the
clinical use of IUdR as a radiation sensitiser in patients with solid
cancers. In the initial studies, tumour-bearing mice received
intravenous bolus doses of 24mgkg
 1 of IUdR, either in the form
of unencapsulated IUdR or PLIUdR, 16h before receiving SFRT at
doses of either 4.5 or 9Gy. In subsequent studies, an attempt was
made to model the clinical experience with IUdR in which
prolonged intravenous infusions of the drug have been adminis-
tered as loading doses before RT. Therefore, four separate
intravenous bolus doses of 12mgkg
 1 of either unencapsulated
IUdR or PLIUdR were administered on alternate days over a 7-day
period ( 8t o 1 days) before SFRT was delivered to a dose of
either 4.5 or 9Gy. Following on from the studies using SFRT, a
number of studies of FRT were performed in which IUdR was
administered according to the protracted loading schedule.
Tumour-bearing mice received total doses of 48mgkg
 1 of IUdR,
either as four doses of 12mgkg
 1 of unencapsulated IUdR or
PLIUdR or as a subcutaneous infusion of unencapsulated IUdR
administered over a 7-day period as described above. FRT was
administered to doses of either 9Gy in three fractions over 3 days
or 15Gy in five fractions over 5 days.
Immunohistochemistry
The monoclonal anti-BUdR antibody (clone BU-1), which
recognises both IUdR and BUdR, was used (Amersham
International plc, Amersham, UK). KB tumour-bearing animals
(three for each treatment) received total doses of 48mgkg
 1 of
IUdR, either as four doses of 12mgkg
 1 of PLIUdR or as a
subcutaneous infusion of unencapsulated IUdR administered via
Alzet
s Model 2002 miniosmotic pumps over a 7-day period as
described above. Control animals received four bolus injections of
PBS over the same time course as that used for PLIUdR. The
tumours were removed 24h after completion of IUdR administra-
tion and fixed in formalin at 41C for 3 days. Thereafter, they were
embedded in paraffin and 5mm sections were cut and mounted on
slides coated with 0.1% poly-L-lysine (Sigma, Poole, UK), dried
overnight and stored at room temperature until use. The slides
were dewaxed and rehydrated through solutions of xylene, alcohol
and water. They were then incubated overnight at 41C with 50mlo f
BU-1 antibody that had previously been biotinylated (3–4
molecules per molecule of antibody). After this incubation,
streptavidin–horseradish peroxidase (Dako Ltd, High Wycombe,
UK) was added and subsequent colorimetric visualisation was
achieved by addition of 50ml 3,30-diaminobenzidine (BDH
Laboratory Supplies, Poole, UK) solution at a concentration of
0.3mgml
 1.
Toxicity assessment
Serial measurements of animal weight were used as a surrogate
measure of systemic toxicity. The cutaneous radiation reaction in
the treated area was observed in all treatment groups. No attempt
was made to measure haematological or biochemical parameters.
Statistical analysis
Relative tumour volumes were recorded for each animal in a
treatment group. The times taken to reach 3V0 were recorded as an
indication of the progression of the xenograft tumours as
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sdescribed above. The Wilcoxon rank-sum test was used to test the
difference between the times taken to reach 3V0 in the various test
groups. Differences were considered to be significant at Po0.05.
RESULTS
In vitro radiation response of SCCHN cells
The effect of unencapsulated IUdR at concentrations between 10
 4
and 10
 6 M on the survival of HN5 and KB cells after irradiation is
presented in Figure 1A and B. Significant radiosensitisation was
seen at the 10
 4 M concentration for both the 4 and 7Gy radiation
doses in each cell line. This effect was more pronounced in the KB
cells (Figure 1B) and this cell line was used for subsequent
experiments.
TRI after in vitro exposure of KB tumour cells
The retention times for C, G, T, A and IUdR, were 4.670.4,
5.070.4, 6.270.2, 7.370.2 and 10.870.2min, respectively. IUdR
was preferentially detected at 288nm and the deoxynucleotides at
254nm. The compositions of all the deoxynucleotides showed
good agreement between control and treated cells, with the
exception of thymidine that was partially replaced by IUdR in
treated cells. The percentage substitution by IUdR was equal to the
percentage by which thymidine was decreased from the control
cells, suggesting that thymidine was substituted by IUdR without
any other effect on the base content of the DNA (Table 1).
SFRT and single bolus IUdR
The results of SFRT at doses of 4.5 and 9Gy delivered 16h after a
single bolus injection of 24mgkg
 1 of either unencapsulated IUdR
or PLIUdR are presented in Table 2. As compared to the untreated
controls, neither unencapsulated IUdR nor PLIUdR alone exerted a
significant effect on tumour growth. In combination with SFRT
doses of 4.5 and 9Gy, there was no evidence of enhancement of the
radiation response with either agent (data not shown). These
results prompted attempts to increase the area under the curve of
tumour exposure to IUdR by using more protracted dosing
schedules.
SFRT and protracted administration of IUdR
The effect of repeated bolus administration of unencapsulated
IUdR and PLIUdR (total dose 48mgkg
 1 over 7 days) before SFRT
at doses of either 4.5 and 9Gy on the growth of KB xenograft
tumours is shown in Table 3. Once again, neither of these agents
exerted a significant independent effect on tumour growth (data
not shown). When administered according to this protracted
schedule, PLIUdR significantly increased the effect of SFRT at a
dose of 4.5Gy (Po0.01) but not at a dose of 9Gy (P40.1). There
was no evidence of enhancement of the effect of SFRT at either
dose level with unencapsulated IUdR (P40.1). Furthermore, a
direct comparison between the effects of PLIUdR and unencapsu-
lated IUdR revealed no significant difference at 4.5 or 9Gy (P40.1
for both comparisons). There was no evidence of increased local
cutaneous radiation toxicity with unencapsulated IUdR or PLIUdR
at either radiation dose.
FRT and protracted administration of IUdR
The effect of FRT to a dose of either 9Gy in three fractions in 3
days (9Gy in 3F) or 15Gy in five fractions in 5 days (15Gy in 5F)
in combination with either a subcutaneous infusion of 48mgkg
 1
of unencapsulated IUdR or four bolus injections of 12mgkg
 1 of
PLIUdR over 7 days on the growth of KB tumour xenografts is
shown in Table 4 and in Figure 2A and B. When administered
according to this schedule, PLIUdR significantly increased the
effect of FRT at doses of both 9Gy in 3F (Po0.05) and 15Gy in 5F
Gy (Po0.01). However, the subcutaneous infusion of unencapsu-
lated IUdR did not significantly increase the effect of either dose of
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Figure 1 Effect of IUdR treatment on the response of SCCHN cells to
irradiation: (A) HN5 cells; (B) KB cells. Cells were exposed to 0, 1, 10 or
100mM unencapsulated IUdR for 48h and then irradiated (0, 4 or 7Gy)
with a
137Cs source at a dose rate of 2Gymin
 1. Following irradiation, cells
were incubated for 6 days and a p-nitrophenyl-N-acetyl-b-D-glucosaminide
(NAG) cell survival assay was performed. Significant radiosensitisation was
seen at the 100mM concentration for both the 4 and 7Gy radiation doses
in each cell line. The effect of IUdR was most pronounced for the KB cells
and this cell line was selected for subsequent in vitro and in vivo analysis.
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sFRT, although at the dose of 15Gy in 5F it was of borderline
significance (0.14P40.05). A direct comparison between the
effects of multiple dose PLIUdR and subcutaneous unencapsulated
IUdR revealed no significant difference at either dose of FRT
(P40.1 for both comparisons). There was no evidence of increased
local radiation toxicity with subcutaneous unencapsulated IUdR or
PLIUdR at either FRT dose.
Immunohistochemistry
The results of staining tumour specimens from animals treated
with PBS, unencapsulated IUdR and PLIUdR with BU-1 mono-
clonal antibody are presented in Figure 3A, B and C, respectively.
Significant positive staining of the nuclei of tumour cells was seen
in animals treated with PLIUdR and, to a lesser extent,
unencapsulated IUdR. In contrast, there was virtually no tumour
staining seen in the animals treated with PBS.
Toxicity
There was no significant alteration in the weight of mice that
received single intravenous bolus doses of 24mgkg
 1 of either
unencapsulated IUdR or PLIUdR, SFRT or combinations of these
two treatments (data not shown). However, multiple intravenous
injections of either unencapsulated IUdR or PLIUdR were
associated with a temporary reduction in the animals’ weights
(o10%) over the week during which the injections were
administered (data not shown). No such alteration was detected
for the animals that had the subcutaneous infusion pumps inserted
(data not shown). All groups that received FRT experienced a
reversible 6–15% reduction in mean weight during the first 10
days of the study (data not shown). There was no evidence of
enhanced cutaneous radiation reaction in any of the treatment
groups (data not shown).
DISCUSSION
In recent years, radiosensitising agents (cytotoxic drugs, hyperba-
ric oxygen, hypoxic cell sensitisers and HP) have been shown to
improve the response rate and outcome of radical RT in a range of
tumour types, including head and neck cancer (McGinn and
Kinsella 1992; Munro 1995; Saunders and Dische 1996; Overgaard
et al, 1998; Pignon et al, 2000). However, the combined use of RT
and radiosensitising agents has a number of potential drawbacks:
increased local normal tissue radiation toxicity that may
necessitate radiation dose reductions and treatment delays
(Tannock, 1996); increased late local radiation morbidity (Henk,
1997); and dose-limiting systemic toxicities. Liposome delivery
offers the prospect of reducing or circumventing each of these
problems by targeting delivery of the radiosensitiser preferentially
to the tumour tissue and avoiding local and distant normal tissue
deposition of the drug. We have recently provided proof of
principle for this strategy using RT and liposomal doxorubicin and
cisplatin in a KB tumour xenograft model (Harrington et al,
2000b). However, since each of those agents has been shown to
have a demonstrable antitumour effect in this model (Harrington
et al, 2000c), it was difficult to be clear that they were acting as true
radiosensitisers.
In this study, we have demonstrated that a novel prodrug
formulation of IUdR encapsulated within pegylated liposomes has
Table 1 Thymidine replacement indices (TRI) for KB cells after 48h
period of exposure to unencapulated IUdR at concentrations between 0
and 100mM
IUdR concentration (lM) TRI Thymidine content in DNA (%)
0 0 29.8
1 2.2 27.6
10 2.8 27
100 7 22.8
Table 2 Effect of single dose unencapsulated IUdR or PLIUdR
24mgkg
 1 plus single fraction RT against KB xenograft tumours in nude
mice
Median time to 3V0 (days)
Group 4.5Gy 9Gy
No drug 12.7 22.6
Unencapsulated IUdR plus RT 14.0 21.9
PLIUdR plus RT 12.4 22.7
P
Group 4.5Gy 9Gy
RT vs unencapsulated IUdR plus RT 40.1 40.1
RT vs PLIUdR plus RT 40.1 40.1
Unencapsulated IUdR plus RT vs PLIUdR plus RT 40.1 40.1
Median times to 3V0 and statistical analysis.
Table 3 Effect of multiple dose unencapsulated IUdR or PLIUdR
(4 12mgkg
 1) plus single fraction RT against KB xenograft tumours in
nude mice
Median time to 3V0 (days)
Group 4.5Gy 9Gy
No drug 12.7 22.6
Unencapsulated IUdR plus RT 13.7 24.3
PLIUdR plus RT 16.8 26.7
P
Group 4.5Gy 9Gy
RT vs unencapsulated IUdR plus RT 40.1 40.1
RT vs PLIUdR plus RT o0.01 40.1
Unencapsulated IUdR plus RT vs PLIUdR plus RT 40.1 40.1
Median times to 3V0 and statistical analyses.
Table 4 Effect of a subcutaneous infusion of unencapsulated IUdR
(48mgkg
 1) or multiple dose PLIUdR (4 12mgkg
 1) plus fractionated
RT on KB xenograft tumours in nude mice
Median time
to 3V0 (days)
Group 9Gy in 3F 15Gy in 5F
RT alone 13.2 18.8
sc unencapsulated IUdR 48mgkg
 1 plus RT 17.6 26.9
PLIUdR 4 12mgkg
 1 plus RT 21.6 34.2
P
Group 9Gy in 3F 15Gy in 5F
RT vs sc unencapsulated IUdR plus RT 40.1 0.14P40.05
RT vs PLIUdR plus RT o0.05 o0.01
sc unencapsulated IUdR plus RT vs PLIUdR plus RT 40.1 40.1
Median times to 3V0 and statistical analyses.
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sno intrinsic antitumour efficacy but is able to enhance the effect of
both SFRT and FRT in a HNSCC xenograft model in nude mice.
Significantly, the liposomal agent was at least as effective as a
sustained infusion of unencapsulated IUdR. However, it must be
borne in mind that unencapsulated IUdR was not administered
at the maximum tolerated dose in these experiments. Clearly,
future studies will need to compare these two agents at their
maximal tolerated doses in order to provide a more accurate
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Figure 2 Effect of a subcutaneous infusion of unencapsulated IUdR (48mgkg
 1) or four intravenous doses of 12mgkg
 1 PLIUdR (total dose 48mgkg
 1)
on the response of KB xenograft tumours to fractionated irradiation: (A) 9Gy in three fractions over 3 days; (B) 15Gy in five fractions over 5 days. Test
agents were administered over a period of 7 days terminating 16h before the delivery of the first dose of FRT. PLIUdR administered according to this
protracted schedule enhanced the effect of both FRT schedules (Po0.05 for 9Gy in three fractions; Po0.01 for 15Gy in five fractions). The effect of
unencapsulated IUdR did not reach statistical significance.
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spicture of the radiosensitising effect of this liposomal prodrug
formulation.
These data have considerable significance for the development
of clinical strategies using pegylated liposomal radiosensitisers. In
clinical practice, the conventional means of delivering IUdR has
involved prolonged intravenous infusions over a period of up to 14
days before commencing RT (Speth et al, 1988; Cook et al, 1992;
Goffman et al, 1992; Urtasun et al, 1993; Epstein et al, 1994;
Sullivan et al, 1994; Robertson et al, 1995; Urtasun et al, 1996).
Such schedules have been associated with appreciable systemic
hematological toxicity and local catheter-related infusion site
reactions and have effectively prevented the development of this
promising agent for clinical use (Goffman et al, 1992; Urtasun et al,
1993; Sullivan et al, 1994; Epstein et al, 1994; Robertson et al, 1995;
Urtasun et al, 1996). The data presented here suggest that
administration of a small number of short-duration intravenous
infusions of dpIUdR encapsulated in pegylated liposomes could
achieve an equivalent radiosensitising effect as more prolonged
intravenous infusions. Further studies will be required to
determine if the liposomal agent is as active as protracted delivery
of unencapsulated drug at the maximum tolerated dose. Although
there was no direct assessment of toxicity in these studies,
previous clinical experience with myelotoxic agents, such as
doxorubicin, entrapped in pegylated liposomes has revealed
attenuation of haematological toxicity (Muggia et al, 1997; Ranson
et al, 1997).
The examination of the effect of various schedules of admin-
istration of unencapsulated IUdR and PLIUdR provides some
useful insights into the use of these agents. Enhancement of the
radiation response was not evident after single bolus injections of
either agent delivered 16h (approximately one in vitro doubling
time) before SFRT at doses of 4.5 and 9Gy. This lack of activity of
PLIUdR may have been accentuated by relatively slow kinetics of
conversion of the lipophilic prodrug to its hydrophilic active
component and its subsequent diffusion into the interior of
tumour cells to be incorporated into their DNA. However,
when the IUdR was delivered according to a protracted
administration schedule (approximately 10 in vitro doubling
times), this resulted in enhanced efficacy of the SFRT and
FRT doses. These findings are in keeping with the previously
published preclinical and clinical data which suggest that for
meaningful radiosensitisation to occur IUdR should be present
for a prolonged period to ensure maximal labelling of tumour
cells (Goffman et al, 1992; Urtasun et al, 1993; Epstein
et al, 1994; Sullivan et al, 1994; Robertson et al, 1995; Fowler
and Kinsella, 1996; Urtasun et al, 1996). The administration of
unencapsulated IUdR by continuous subcutaneous infusion
and PLIUdR by multiple bolus injections appeared to be an
effective means of achieving this objective. Previous studies in
nude mice bearing KB xenograft tumours have shown that
111In-
DTPA-labelled pegylated liposomes have a prolonged circulation
half-life of approximately 10h and achieve maximal tumour
uptake at 24h after intravenous injection (Harrington et al,
2000d). Biodistribution and pharmacokinetic studies in patients
with solid cancers have demonstrated similar data, with a
circulation half-life of approximately 75h and maximal tumour
uptake at 48–72h (Harrington et al, 2001b). Therefore, progres-
sive accumulation of PLIUdR within tumour deposits may
effectively act as a local, prolonged, high-concentration infusion
of the agent precisely in the site where it is likely to exert
maximum efficacy.
Therefore, in summary, this novel prodrug formulation of IUdR
encapsulated in pegylated liposomes appears to offer considerable
promise for further development. Indeed, preliminary pharmaco-
kinetic and biodistribution studies have commenced in patients
with head and neck cancer.
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Figure 3 Immunohistochemistry of KB tumours from animals treated
with (A) intravenous phosphate-buffered saline (four doses of 100ml over
7 days); (B) unencapsulated IUdR 48mgkg
 1 as a continuous subcuta-
neous infusion over 7 days; (C) intravenous PLIUdR (four doses of
12mgkg
 1 over 7 days). Paraffin-embedded sections were stained with
biotinylated BU-1 monoclonal antibody followed by incubation with
streptavidin–horseradish peroxidase and addition of 3,30-diaminobenzi-
dine. No positive staining was seen in the phosphate-buffered saline-
treated group. The animals treated with unencapsulated IUdR showed low
levels of staining. There was very prominent nuclear staining in the animals
treated with PLIUdR.
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